Cypherpunk Technologies
47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts, 02141, United States
Overview
Cypherpunk Technologies is a biopharmaceutical company developing antibody therapies for cancer while simultaneously executing a digital-asset treasury strategy centered on Zcash. Their oncology pipeline includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK-1, and FL-501, another antibody in preclinical development.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 6
Sector focus
- Biotechnology
- FinTech
- Life Science
- Medical
- Oncology
Investment portfolio
- Zcash Open Development Lab
Participated · Seed · Mar 2026
Zcash Open Development Lab (ZODL) is an independent development group formed by the former engineering and product team of the Electric Coin Company (ECC) after their January 2026 resignation. Led by former ECC CEO Josh Swihart, the lab is responsible for advancing the core Zcash protocol and building user-friendly privacy tools. Its flagship product is Zodl (formerly Zashi), a self-custodial mobile wallet that enables shielded ZEC transactions using zero-knowledge cryptography. Since launching in 2024, Zodl has driven more than a 400% increase in Zcash’s shielded pool activity and has processed over $600 million in ZEC swaps since October. The team plans to hire additional engineers and expand product features to make private digital payments easier for everyday users. ZODL operates independently of ECC, which remains under the nonprofit Bootstrap, but continues to handle much of the network’s core software work.